Chendan Zou

790 total citations
13 papers, 558 citations indexed

About

Chendan Zou is a scholar working on Molecular Biology, Cancer Research and Toxicology. According to data from OpenAlex, Chendan Zou has authored 13 papers receiving a total of 558 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Cancer Research and 2 papers in Toxicology. Recurrent topics in Chendan Zou's work include Circular RNAs in diseases (5 papers), MicroRNA in disease regulation (4 papers) and Cancer-related molecular mechanisms research (3 papers). Chendan Zou is often cited by papers focused on Circular RNAs in diseases (5 papers), MicroRNA in disease regulation (4 papers) and Cancer-related molecular mechanisms research (3 papers). Chendan Zou collaborates with scholars based in China and Kenya. Chendan Zou's co-authors include Xu Gao, Chaoxia Zou, Xishan Wang, Qingchao Tang, Qiang Li, Qian Zhang, He Zhang, Xiaona Wang, Jianfeng Jin and Weiming Zhao and has published in prestigious journals such as Nucleic Acids Research, PLoS ONE and Life Sciences.

In The Last Decade

Chendan Zou

13 papers receiving 551 citations

Peers

Chendan Zou
Chendan Zou
Citations per year, relative to Chendan Zou Chendan Zou (= 1×) peers Xiaoling Luo

Countries citing papers authored by Chendan Zou

Since Specialization
Citations

This map shows the geographic impact of Chendan Zou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chendan Zou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chendan Zou more than expected).

Fields of papers citing papers by Chendan Zou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chendan Zou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chendan Zou. The network helps show where Chendan Zou may publish in the future.

Co-authorship network of co-authors of Chendan Zou

This figure shows the co-authorship network connecting the top 25 collaborators of Chendan Zou. A scholar is included among the top collaborators of Chendan Zou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chendan Zou. Chendan Zou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
2.
Zou, Chendan, Yuan Yu, Hefei Wang, et al.. (2023). Juglone Inhibits Tumor Metastasis by Regulating Stemness Characteristics and the Epithelial-to-Mesenchymal Transition in Cancer Cells both in Vitro and in Vivo. Frontiers in Bioscience-Landmark. 28(2). 26–26. 3 indexed citations
3.
Tang, Hao, Xuemei Zhang, Chendan Zou, et al.. (2023). Hepatocyte growth factor-modified hair follicle stem cells ameliorate cerebral ischemia/reperfusion injury in rats. Stem Cell Research & Therapy. 14(1). 25–25. 10 indexed citations
4.
Zhang, He, Chongyang Wang, Yuanli Liu, et al.. (2021). CPEB3 deficiency in mice affect ovarian follicle development and causes premature ovarian insufficiency. Cell Death and Disease. 13(1). 21–21. 16 indexed citations
5.
Zhang, He, Chendan Zou, Dayong Wang, et al.. (2020). CPEB3-mediated MTDH mRNA translational suppression restrains hepatocellular carcinoma progression. Cell Death and Disease. 11(9). 792–792. 34 indexed citations
6.
Wang, Hefei, Chendan Zou, Weiyang Zhao, et al.. (2019). Juglone eliminates MDSCs accumulation and enhances antitumor immunity. International Immunopharmacology. 73. 118–127. 22 indexed citations
7.
Zhang, Yongjian, He Zhang, Chao Zhan, et al.. (2018). CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research. 37(1). 46–46. 57 indexed citations
8.
Zou, Chaoxia, Chendan Zou, Wanpeng Cheng, et al.. (2016). Heme oxygenase-1 retards hepatocellular carcinoma progression through the microRNA pathway. Oncology Reports. 36(5). 2715–2722. 42 indexed citations
9.
Zhang, Qian, Lei Yu, Dandan Qin, et al.. (2015). Role of microRNA-30c Targeting ADAM19 in Colorectal Cancer. PLoS ONE. 10(3). e0120698–e0120698. 49 indexed citations
10.
Zou, Chendan, Weiming Zhao, Xiaona Wang, et al.. (2015). MicroRNA-107: a novel promoter of tumor progression that targets the CPEB3/EGFR axis in human hepatocellular carcinoma. Oncotarget. 7(1). 266–278. 54 indexed citations
11.
Tang, Qingchao, Chendan Zou, Qian Zhang, et al.. (2014). MicroRNA-93 suppress colorectal cancer development via Wnt/β-catenin pathway downregulating. Tumor Biology. 36(3). 1701–1710. 78 indexed citations
12.
Li, Qiang, Chaoxia Zou, Chendan Zou, et al.. (2013). MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Letters. 335(1). 168–174. 102 indexed citations
13.
Li, Chunquan, Junwei Han, Qianlan Yao, et al.. (2013). Subpathway-GM: identification of metabolic subpathways via joint power of interesting genes and metabolites and their topologies within pathways. Nucleic Acids Research. 41(9). e101–e101. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026